BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 25, 2010
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Warner Chilcott, Novartis sales and marketing update

Warner Chilcott completed its previously announced acquisition of the U.S. rights to commercialize Enablex darifenacin to treat overactive bladder (OAB) from co-promotion partner Novartis for $400 million in cash...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >